Please login to the form below

Not currently logged in
Email:
Password:

Cosentyx

This page shows the latest Cosentyx news and features for those working in and with pharma, biotech and healthcare.

UCB looks to pipeline with five years left for twin blockbusters

UCB looks to pipeline with five years left for twin blockbusters

This goes one step further than two similar drugs already on the market – Novartis’ Cosentyx and Lilly’s Taltz which specifically inhibit IL-17A.

Latest news

  • Greater Manchester backs move to outcome-based payment Greater Manchester backs move to outcome-based payment

    One company which has launched its own UK-specific outcomes guarantee deal with local NHS organisations is Novartis, for its psoriasis treatment Cosentyx.

  • Novartis aims for 10 blockbuster launches by 2020 Novartis aims for 10 blockbuster launches by 2020

    Among its revenue-earners, Cosentyx is proving to be a star performer, with revenues rising 36% over the last 12 months to reach full year sales of $2.8bn. ... Zolgensma – spinal muscular atrophy (SMA) type 1. 2020. Cosentyx Non-Radiographic Axial

  • J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

    Novartis’ Cosentyx can put some of its fast growth in psoriasis down to data showing it was more effective than Johnson &Johnson’s widely-used Stelara, but a new trial has ... In a head-to-head challenge, J&J’s recently approved follow-up to

  • Novartis gains label boost for Cosentyx Novartis gains label boost for Cosentyx

    Cosentyx has been in the psoriatic arthritis (PsA) market for almost four years now, and has also established itself in plaque psoriasis and ankylosing spondylitis. ... Cosentyx is the only IL-17A inhibitor to demonstrate 5-year safety and efficacy in

  • Novartis buys cancer specialist Endocyte for $2.1bn Novartis buys cancer specialist Endocyte for $2.1bn

    Cosentyx saw its sales rise 37%. News of the latest bolt-on deal came as Novartis revealed a 6% rise in third-quarter sales to $12.8bn in constant currencies on ... the back of gains for new psoriasis drug Cosentyx (secukinumab) and Entresto

More from news
Approximately 23 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    An Outcomes Guarantee model - Cosentyx promise. Among the many initiatives Novartis is working on with the NHS is ‘The Cosentyx Promise’. ... Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee.

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Maker Projects

    Our clients include: The NHS NWEH Cancer Research Cosentyx / Novartis Brilinta / AstraZeneca Port of Call We have branches in Manchester and London - to find out more: www.makerprojects.co.

  • 90TEN nominated for five Communiqué Awards

    Year. 90TEN’s work with Novartis on the global launch of Cosentyx is nominated for Excellence in Media Relations.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics